Sigilon Therapeutics Inc - ESG Rating & Company Profile powered by AI
Comprehensive Sustainability assessment of Sigilon Therapeutics Inc can be reached by logging in. Browse to the end of this page for potential risks for Sigilon Therapeutics Inc based on sector, geography and size. This article contains a Q&A section on Sigilon Therapeutics Inc.
Sigilon Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 8.0, social score of 1.6 and governance score of 6.0.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 658 | Transchem Ltd | 5.3 | High |
| 658 | Zenith Healthcare Ltd | 5.3 | High |
| 687 | Sigilon Therapeutics Inc | 5.2 | High |
| 687 | Cardiol Therapeutics Inc | 5.2 | High |
| 687 | Cell Source Inc | 5.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Sigilon Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Sigilon Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Sigilon Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Sigilon Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Sigilon Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Sigilon Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Sigilon Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Sigilon Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Sigilon Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Sigilon Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Sigilon Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Sigilon Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Sigilon Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Sigilon Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Sigilon Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Sigilon Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Sigilon Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Sigilon Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.